Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis.
To assess the benefit of the recombinant human interleukin-1 receptor antagonist, anakinra, in treating pediatric patients with secondary hemophagocytic lymphohistiocytosis (sHLH) / macrophage activation syndrome (MAS) associated with rheumatologic and non-rheumatologic conditions. We performed a retrospective chart review of all anakinra-treated sHLH/MAS patients at Children's of Alabama from January 2008 through December 2016. Demographic, clinical, laboratory, genetic, concurrent treatment, and outcome data were collected and analyzed by appropriate univariate statistical approaches. Forty-four sHLH/MAS patients treated with anakinra were identified in the electronic medical record. Median duration of hospitalization was 15 days. The mean pre-treatment serum ferritin level was 33,316 ng/mL and dropped to 14,435 (57% decrease) within 15 days of starting anakinra. The overall mortality for the cohort was 27%. Earlier initiation of anakinra (≤5 days hospitalization) was associated with reduced mortality (p=0.046), whereas thrombocytopenia (<100,000/μL) and STXBP2 mutations were both associated with increased mortality (p=0.008 and p=0.012, respectively). Considering the underlying diagnosis, systemic juvenile idiopathic arthritis (sJIA) had the lowest mortality rate, with no deaths among the 13 sJIA patients included in the study (p=0.006). In contrast, underlying hematologic malignancy had the highest mortality rate at 100% (n=3). These findings suggest anakinra appears to be effective in non-malignancy associated pediatric sHLH, especially when given early in disease course and in patients with an underlying rheumatic disease etiology. This article is protected by copyright. All rights reserved.